This is a Validated Antibody Database (VAD) review about pig SPARC, based on 17 published articles (read how Labome selects the articles), using SPARC antibody in all methods. It is aimed to help Labome visitors find the most suited SPARC antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
SPARC synonym: SPARC; BM-40; basement-membrane protein 40; osteonectin; secreted protein acidic and rich in cysteine; secreted protein, acidic, cysteine-rich (osteonectin)

Invitrogen
mouse monoclonal (ON1-1)
  • immunohistochemistry; dog; fig 6
In order to elucidate the behavior of canine bone marrow stromal cells during differentiation into osteoblasts utilizing different implant biomaterials, Invitrogen SPARC antibody (Zymed, 33-5500) was used in immunohistochemistry on dog samples (fig 6). Biotech Histochem (2016) ncbi
mouse monoclonal (ON1-1)
  • immunocytochemistry; human; fig 1
In order to characterize the growth and attachment of dental pulp stem cells on dentin with extra calcium, Invitrogen SPARC antibody (Zymed, 33-5500) was used in immunocytochemistry on human samples (fig 1). Arch Oral Biol (2016) ncbi
mouse monoclonal (ON1-1)
  • ELISA; human
In order to optimize a method to distinguish benign prostatic hypertrophy from prostate cancer, Invitrogen SPARC antibody (Invitrogen, 33-5500) was used in ELISA on human samples . PLoS ONE (2015) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry; human; 1:400; fig 1
In order to evaluate carboplatin with nanoparticle albumin-bound-paclitaxel as first-line therapy for advanced non-small-cell lung cancer in a phase II trail, Invitrogen SPARC antibody (Invitrogen, 33-5500) was used in immunohistochemistry on human samples at 1:400 (fig 1). Clin Lung Cancer (2015) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry; dog; fig 5
In order to assess the use of cultured autologous bone marrow stromal cells on different scaffolds for healing defects in the tibias of dogs, Invitrogen SPARC antibody (Zymed, 33-5500) was used in immunohistochemistry on dog samples (fig 5). Biotech Histochem (2015) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry; human; 1:100
In order to evaluate the vasculogenic mimicry as a prognostic marker of human osteosarcoma, Invitrogen SPARC antibody (Invitrogen, 33-5500) was used in immunohistochemistry on human samples at 1:100. Hum Pathol (2014) ncbi
mouse monoclonal (ON1-1)
  • ELISA; human; fig 1
In order to test if the concentrations of SPARC are altered in patients with gestational diabetes mellitus, Invitrogen SPARC antibody (Life Technologies, ON1-1) was used in ELISA on human samples (fig 1). PLoS ONE (2013) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry; human; 1:1000; fig 3
In order to test if the desmoid-type fibromatosis signature is specific to breast cancer or if it is found in multiple types of cancer, Invitrogen SPARC antibody (Invitrogen, 33-5500) was used in immunohistochemistry on human samples at 1:1000 (fig 3). Clin Cancer Res (2013) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry - paraffin section; human; 10 ug/ml; fig 2
In order to examine the characteristics of the extracellular matrix and its impact on tumor progression, Invitrogen SPARC antibody (ZYMED, clone ON1-1) was used in immunohistochemistry - paraffin section on human samples at 10 ug/ml (fig 2). PLoS ONE (2013) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry; rat; fig 5
In order to determine the effects of zoledronic acid on bone regeneration in response to expansion of the sagittal suture and relapse in rats, Invitrogen SPARC antibody (Zymed, 33-5500) was used in immunohistochemistry on rat samples (fig 5). Am J Orthod Dentofacial Orthop (2011) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry - paraffin section; human; 1:6000; fig 1
In order to identify immunohistochemical markers to aid chondroid tumor diagnosis, Invitrogen SPARC antibody (Zymed, ON1-1) was used in immunohistochemistry - paraffin section on human samples at 1:6000 (fig 1). APMIS (2009) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry; human
In order to investigate the molecular mechanism of bone remodeling with osteoclasts and osteoblasts, Invitrogen SPARC antibody (Zymed, ON1-1) was used in immunohistochemistry on human samples . Am J Pathol (2009) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry - paraffin section; human; 1:500
In order to examine DNA methylation in intraductal papillary mucinous neoplasms, Invitrogen SPARC antibody (Zymed Laboratories, ON1-1) was used in immunohistochemistry - paraffin section on human samples at 1:500. Mod Pathol (2008) ncbi
mouse monoclonal (ON1-1)
  • immunocytochemistry; human; 5 ug/ml; fig 3
  • western blot; human; fig 2
In order to investigate how nonsteroidal anti-inflammatory drugs alter metastasis-related genes, Invitrogen SPARC antibody (Zymed, 33-5500) was used in immunocytochemistry on human samples at 5 ug/ml (fig 3) and in western blot on human samples (fig 2). Exp Biol Med (Maywood) (2008) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry - paraffin section; human
In order to assess the prognostic significance of tumor and peritumoral secreted protein acidic and rich in cysteine expression in patients with pancreatic adenocarcinoma, Invitrogen SPARC antibody (Zymed, ON1-1) was used in immunohistochemistry - paraffin section on human samples . J Clin Oncol (2007) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry; human; 1:200; fig 8B
  • western blot; human; 1:1000
In order to study the role of SPARC expression in impaired tumor growth, inhibited angiogenesis and extracellular matrix changes, Invitrogen SPARC antibody (Zymed, ON1-1) was used in immunohistochemistry on human samples at 1:200 (fig 8B) and in western blot on human samples at 1:1000. Int J Cancer (2006) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry; human; fig 2
In order to report the expression pattern and methylation status of the SPARC gene in pancreatic cancer, Invitrogen SPARC antibody (Zymed, ON1-1) was used in immunohistochemistry on human samples (fig 2). Oncogene (2003) ncbi
Articles Reviewed
  1. Ozdal Kurt F, Tuglu I, Vatansever H, Tong S, Sen B, Deliloglu Gurhan S. The effect of different implant biomaterials on the behavior of canine bone marrow stromal cells during their differentiation into osteoblasts. Biotech Histochem. 2016;91:412-22 pubmed publisher
  2. Ozdal Kurt F, Sen B, Tuglu I, Vatansever S, Türk B, Deliloglu Gurhan I. Attachment and growth of dental pulp stem cells on dentin in presence of extra calcium. Arch Oral Biol. 2016;68:131-41 pubmed publisher
  3. Jokerst J, Chen Z, Xu L, Nolley R, Chang E, Mitchell B, et al. A Magnetic Bead-Based Sensor for the Quantification of Multiple Prostate Cancer Biomarkers. PLoS ONE. 2015;10:e0139484 pubmed publisher
  4. Bertino E, Williams T, Nana Sinkam S, Shilo K, Chatterjee M, Mo X, et al. Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients. Clin Lung Cancer. 2015;16:466-74 pubmed publisher
  5. Özdal Kurt F, Tuğlu I, Vatansever H, Tong S, Deliloğlu Gürhan S. The effect of autologous bone marrow stromal cells differentiated on scaffolds for canine tibial bone reconstruction. Biotech Histochem. 2015;90:516-28 pubmed publisher
  6. Ren K, Yao N, Wang G, Tian L, Ma J, Shi X, et al. Vasculogenic mimicry: a new prognostic sign of human osteosarcoma. Hum Pathol. 2014;45:2120-9 pubmed publisher
  7. Xu L, Ping F, Yin J, Xiao X, Xiang H, Ballantyne C, et al. Elevated plasma SPARC levels are associated with insulin resistance, dyslipidemia, and inflammation in gestational diabetes mellitus. PLoS ONE. 2013;8:e81615 pubmed publisher
  8. Chen J, Espinosa I, Lin A, Liao O, van de Rijn M, West R. Stromal responses among common carcinomas correlated with clinicopathologic features. Clin Cancer Res. 2013;19:5127-35 pubmed publisher
  9. Triulzi T, Casalini P, Sandri M, Ratti M, Carcangiu M, Colombo M, et al. Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress. PLoS ONE. 2013;8:e56761 pubmed publisher
  10. Ozturk F, Babacan H, Inan S, Gumus C. Effects of bisphosphonates on sutural bone formation and relapse: A histologic and immunohistochemical study. Am J Orthod Dentofacial Orthop. 2011;140:e31-41 pubmed publisher
  11. Daugaard S, Christensen L, Høgdall E. Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40. APMIS. 2009;117:518-25 pubmed publisher
  12. Andersen T, Sondergaard T, Skorzynska K, Dagnaes Hansen F, Plesner T, Hauge E, et al. A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol. 2009;174:239-47 pubmed publisher
  13. Hong S, Kelly D, Griffith M, Omura N, Li A, Li C, et al. Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. Mod Pathol. 2008;21:1499-507 pubmed publisher
  14. Pan M, Chang H, Chuang L, Hung W. The nonsteroidal anti-inflammatory drug NS398 reactivates SPARC expression via promoter demethylation to attenuate invasiveness of lung cancer cells. Exp Biol Med (Maywood). 2008;233:456-62 pubmed publisher
  15. Infante J, Matsubayashi H, Sato N, Tonascia J, Klein A, Riall T, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol. 2007;25:319-25 pubmed
  16. Chlenski A, Liu S, Guerrero L, Yang Q, Tian Y, Salwen H, et al. SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. Int J Cancer. 2006;118:310-6 pubmed
  17. Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, Su G, et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene. 2003;22:5021-30 pubmed